How much does it cost to purchase brigatinib for one month and risk description

Brigatinib (Brigatinib) is a targeted drug used to treat ALK positive non-small cell lung cancer. It has been officially launched in China and has been included in the medical insurance system. This means that patients can purchase it through regular hospitals and pharmacies and enjoy the medical insurance reimbursement policy, which greatly reduces the burden of medication. The price of brigatinib in the domestic market is about four to five thousand yuan a month, but the specific cost and reimbursement ratio vary depending on regional medical insurance policies. Patients need to consult local medical institutions to obtain accurate information.

Although domestic prices are relatively high, the actual out-of-pocket amount paid by patients is usually more reasonable due to medical insurance coverage, ensuring the continuity and safety of treatment. In contrast, the price of generic brigatinib drugs in foreign markets is significantly low. The price of the generic version produced in Laos is only a few hundred yuan a month, which is far lower than the price of the domestic original drug. The ingredients of this generic drug are basically the same, and its efficacy is also recognized by some patients, so it has become a choice for some patients looking for an economical alternative.

However, there are certain risks in purchasing brigatinib through purchasing agents. First of all, there are legal and regulatory restrictions on cross-border drug procurement. It is difficult to guarantee the source, quality and authenticity of purchased drugs, and there may be risks of counterfeit or inferior drugs. Secondly, the storage conditions during drug transportation are difficult to control, which may affect drug efficacy and bring hidden dangers to patient medication safety. In addition, after-sales service and medication guidance for overseas drugs are limited, making it difficult for patients to obtain timely professional help when adverse reactions occur.

Generally speaking, although purchasing agents are cheaper, patients should give priority to purchasing medicines through formal domestic channels to ensure drug quality and medication safety. For patients who are really facing financial pressure and are considering purchasing on behalf of others, it is recommended that they make careful decisions under the guidance of doctors, understand relevant laws and policies, and avoid drug quality issues that may affect the treatment effect. At the same time, we actively pay attention to the updates of domestic medical insurance policies and drug price changes, and strive to obtain the best treatment experience under the premise of legal compliance.

Reference materials:https://www.alunbrig.com/